Found: 35
Select item for more details and to access through your institution.
Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density.
- Published in:
- Clinical Drug Investigation, 2021, v. 41, n. 3, p. 277, doi. 10.1007/s40261-021-01008-7
- By:
- Publication type:
- Article
Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.
- Published in:
- Journal of Bone & Mineral Research, 2023, v. 38, n. 10, p. 1404, doi. 10.1002/jbmr.4877
- By:
- Publication type:
- Article
Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend.
- Published in:
- Journal of Bone & Mineral Research, 2023, v. 38, n. 4, p. 464, doi. 10.1002/jbmr.4764
- By:
- Publication type:
- Article
The Efficacy and Safety of Abaloparatide‐SC in Men With Osteoporosis: A Randomized Clinical Trial.
- Published in:
- Journal of Bone & Mineral Research, 2022, v. 37, n. 12, p. 2435, doi. 10.1002/jbmr.4719
- By:
- Publication type:
- Article
Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH‐ASBMR SABRE Project.
- Published in:
- Journal of Bone & Mineral Research, 2022, v. 37, n. 1, p. 29, doi. 10.1002/jbmr.4433
- By:
- Publication type:
- Article
Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis.
- Published in:
- Journal of Bone & Mineral Research, 2021, v. 36, n. 4, p. 644, doi. 10.1002/jbmr.4243
- By:
- Publication type:
- Article
Treatment‐Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained.
- Published in:
- Journal of Bone & Mineral Research, 2021, v. 36, n. 2, p. 236, doi. 10.1002/jbmr.4178
- By:
- Publication type:
- Article
The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.
- Published in:
- Journal of Bone & Mineral Research, 2015, v. 30, n. 9, p. 1717, doi. 10.1002/jbmr.2489
- By:
- Publication type:
- Article
A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density.
- Published in:
- 2015
- By:
- Publication type:
- Other
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
- Published in:
- Journal of Bone & Mineral Research, 2011, v. 26, n. 2, p. 397, doi. 10.1002/jbmr.191
- By:
- Publication type:
- Article
Teriparatide for Acceleration of Fracture Repair in Humans: A Prospective, Randomized, Double-Blind Study of 102 Postmenopausal Women With Distal Radial Fractures.
- Published in:
- Journal of Bone & Mineral Research, 2010, v. 25, n. 2, p. 404, doi. 10.1359/jbmr.090731
- By:
- Publication type:
- Article
Quality of Life in Sarcopenia and Frailty.
- Published in:
- Calcified Tissue International, 2013, v. 93, n. 2, p. 101, doi. 10.1007/s00223-013-9758-y
- By:
- Publication type:
- Article
Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
ERRATUMERRATUM for "Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis".
- Published in:
- 2020
- By:
- Publication type:
- journal article
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2020, v. 105, n. 3, p. 938, doi. 10.1210/clinem/dgz162
- By:
- Publication type:
- Article
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene.
- Published in:
- JAMA: Journal of the American Medical Association, 1999, v. 282, n. 7, p. 637, doi. 10.1001/jama.282.7.637
- By:
- Publication type:
- Article
Osteosarcoma and Teriparatide?
- Published in:
- 2007
- By:
- Publication type:
- Letter
Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis.
- Published in:
- Journal of Bone & Mineral Research, 2007, v. 22, n. 1, p. 149, doi. 10.1359/JBMR.061011
- By:
- Publication type:
- Article
Sustained Nonvertebral Fragility Fracture Risk Reduction After Discontinuation of Teriparatide Treatment.
- Published in:
- Journal of Bone & Mineral Research, 2005, v. 20, n. 9, p. 1507, doi. 10.1359/JBMR.050501
- By:
- Publication type:
- Article
Recombinant Human Parathyroid Hormone (1-34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure.
- Published in:
- Journal of Bone & Mineral Research, 2003, v. 18, n. 11, p. 1932, doi. 10.1359/jbmr.2003.18.11.1932
- By:
- Publication type:
- Article
The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis.
- Published in:
- Journal of Bone & Mineral Research, 2003, v. 18, n. 1, p. 18, doi. 10.1359/jbmr.2003.18.1.18
- By:
- Publication type:
- Article
Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy.
- Published in:
- Journal of Bone & Mineral Research, 2002, v. 17, n. 1, p. 1, doi. 10.1359/jbmr.2002.17.1.1
- By:
- Publication type:
- Article
Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.
- Published in:
- Journal of Bone & Mineral Research, 1996, v. 11, n. 4, p. 430, doi. 10.1002/jbmr.5650110403
- By:
- Publication type:
- Article
The effect of systemically administered PDGF-BB on the rodent skeleton.
- Published in:
- Journal of Bone & Mineral Research, 1996, v. 11, n. 2, p. 238, doi. 10.1002/jbmr.5650110213
- By:
- Publication type:
- Article
Accuracy, precision, and utility of spine and whole-skeleton mineral measurements by dxa in rats.
- Published in:
- Journal of Bone & Mineral Research, 1994, v. 9, n. 1, p. 119, doi. 10.1002/jbmr.5650090116
- By:
- Publication type:
- Article
Intermittent administration of bovine PTH-(1-34) increases serum 1,25-dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats.
- Published in:
- Journal of Bone & Mineral Research, 1992, v. 7, n. 5, p. 479, doi. 10.1002/jbmr.5650070503
- By:
- Publication type:
- Article
Pamidronate Reduces PTH-mediated bone loss in a gene transfer model of hyperparathyroidism in rats.
- Published in:
- Journal of Bone & Mineral Research, 1991, v. 6, n. 12, p. 1317, doi. 10.1002/jbmr.5650061208
- By:
- Publication type:
- Article
Asymptomatic primary hyperparathyroidism.
- Published in:
- Journal of Bone & Mineral Research, 1991, v. 6, n. S2, p. S103, doi. 10.1002/jbmr.5650061422
- By:
- Publication type:
- Article
Pharmacogenomics in Endocrinology.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2002, v. 87, n. 6, p. 2495, doi. 10.1210/jcem.87.6.8669
- By:
- Publication type:
- Article
Response rates for lumbar spine, total hip, and femoral neck bone mineral density in men treated with abaloparatide: results from the ATOM study.
- Published in:
- JBMR Plus, 2024, v. 8, n. 2, p. 1, doi. 10.1093/jbmrpl/ziae009
- By:
- Publication type:
- Article
Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.
- Published in:
- JBMR Plus, 2020, v. 4, n. 4, p. 1, doi. 10.1002/jbm4.10346
- By:
- Publication type:
- Article
Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men.
- Published in:
- 2006
- By:
- Publication type:
- Editorial
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
- Published in:
- 2018
- By:
- Publication type:
- journal article